Partners
Research led by leading scientific partners
Real therapeutic breakthroughs come when likeminded innovators work together to drive patient benefits. Our collaborative programmes with leading academics in synbio and immunology are integral to the core of our technology. We are backed by visionary investors who support us in our vision to enable therapeutic efficacy through next generation engineered live biotherapeutics.
Investors
9 of 12
- Co-lead investor
Pioneer Group (opens in a new tab)
thepioneergroup.com
- Co-lead investor
2048 Ventures (opens in a new tab)
2048.vc
- Investor and translational partner
Cancer Research Horizons (opens in a new tab)
cancerresearchhorizons.com
- Investor
Discovery Park Ventures (opens in a new tab)
discovery-park.co.uk
- Investor
Arc Ventures (opens in a new tab)
arc-vc.com
- Investor
Faber (opens in a new tab)
faber.vc
- Impact investor
Macmillan Cancer Support (opens in a new tab)
macmillan.org.uk
- Investor
Proven Connect (opens in a new tab)
provenconnect.com
- Investor
Empirical Ventures (opens in a new tab)
empiricalventures.vc
Partners and funders
3 of 12
01 - Team
Meet our dedicated team of scientists and researchers
Neobe's leadership has decades of combined experience in cancer biology, advanced therapies and bacterial engineering, supported by recognized leaders in oncology business development. Our world class R&D team is committed to a culture of collaboration and inclusion, working together to bring our engineered LBPs to the clinic.
Meet the team